EquitySector - HealthcareVery High Risk
Regular
NAV (27-Mar-25)
Returns (Since Inception)
Fund Size
₹271 Cr
Expense Ratio
2.39%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+28.94%
+17.95% (Cat Avg.)
Since Inception
+23.82%
— (Cat Avg.)
Equity | ₹251.44 Cr | 92.66% |
Others | ₹19.92 Cr | 7.34% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹29.62 Cr | 10.92% |
Cipla Ltd | Equity | ₹21.9 Cr | 8.07% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.1 Cr | 7.41% |
Divi's Laboratories Ltd | Equity | ₹19.07 Cr | 7.03% |
Lupin Ltd | Equity | ₹14.8 Cr | 5.45% |
Fortis Healthcare Ltd | Equity | ₹10.15 Cr | 3.74% |
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹9.56 Cr | 3.52% |
Torrent Pharmaceuticals Ltd | Equity | ₹9.33 Cr | 3.44% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹8.85 Cr | 3.26% |
Mankind Pharma Ltd | Equity | ₹7.54 Cr | 2.78% |
Apollo Hospitals Enterprise Ltd | Equity | ₹6.84 Cr | 2.52% |
Laurus Labs Ltd | Equity | ₹6.41 Cr | 2.36% |
Ipca Laboratories Ltd | Equity | ₹6.17 Cr | 2.27% |
Abbott India Ltd | Equity | ₹5.91 Cr | 2.18% |
Ajanta Pharma Ltd | Equity | ₹5.89 Cr | 2.17% |
Piramal Pharma Ltd | Equity | ₹5.47 Cr | 2.02% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹5.02 Cr | 1.85% |
Poly Medicure Ltd | Equity | ₹4.77 Cr | 1.76% |
Biocon Ltd | Equity | ₹4.77 Cr | 1.76% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹4.72 Cr | 1.74% |
Global Health Ltd | Equity | ₹4.14 Cr | 1.53% |
Jupiter Life Line Hospitals Ltd | Equity | ₹3.78 Cr | 1.39% |
Vijaya Diagnostic Centre Ltd | Equity | ₹3.56 Cr | 1.31% |
Neuland Laboratories Limited | Equity | ₹3.53 Cr | 1.30% |
Rainbow Childrens Medicare Ltd | Equity | ₹3.32 Cr | 1.22% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹3.24 Cr | 1.19% |
Ami Organics Ltd | Equity | ₹3.11 Cr | 1.14% |
Navin Fluorine International Ltd | Equity | ₹3.09 Cr | 1.14% |
91 Days Tbill Red 08-05-2025 | Bond - Gov't/Treasury | ₹2.96 Cr | 1.09% |
Supriya Lifescience Ltd | Equity | ₹2.87 Cr | 1.06% |
AstraZeneca Pharma India Ltd | Equity | ₹2.64 Cr | 0.97% |
Strides Pharma Science Ltd | Equity | ₹2.63 Cr | 0.97% |
Kovai Medical Center & Hospital Ltd | Equity | ₹2.58 Cr | 0.95% |
RPG Life Sciences Ltd | Equity | ₹2.07 Cr | 0.76% |
Thyrocare Technologies Ltd | Equity | ₹1.98 Cr | 0.73% |
Laxmi Dental Ltd | Equity | ₹1.98 Cr | 0.73% |
364 DTB 23052025 | Bond - Gov't/Treasury | ₹1.97 Cr | 0.73% |
Blue Jet Healthcare Ltd | Equity | ₹1.83 Cr | 0.68% |
Sai Life Sciences Ltd | Equity | ₹1.66 Cr | 0.61% |
Net Receivables / (Payables) | Cash | ₹1.65 Cr | 0.61% |
SRF Ltd | Equity | ₹1.55 Cr | 0.57% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹1.52 Cr | 0.56% |
Shaily Engineering Plastics Ltd | Equity | ₹1.22 Cr | 0.45% |
Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.06 Cr | 0.39% |
91 DTB 20032025 | Bond - Gov't/Treasury | ₹1 Cr | 0.37% |
91 DTB 10042025 | Bond - Gov't/Treasury | ₹0.99 Cr | 0.37% |
91 DTB 17042025 | Bond - Gov't/Treasury | ₹0.99 Cr | 0.37% |
Zota Health Care Ltd | Equity | ₹0.72 Cr | 0.26% |
91 Days Tbill Red 24-04-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.18% |
364 DTB 13032025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.07% |
91 DTB 28032025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.04% |
Large Cap Stocks
29.45%
Mid Cap Stocks
32.59%
Small Cap Stocks
28.58%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹238.93 Cr | 88.05% |
Basic Materials | ₹7.42 Cr | 2.74% |
Industrials | ₹1.55 Cr | 0.57% |
Standard Deviation
This fund
--
Cat. avg.
16.58%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.70
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.18
Higher the better
Since February 2024
Since February 2024
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.39% | Exit Load 1.00% | Fund Size ₹271 Cr | Age 1 year 1 month | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹25.63 Cr | 20.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹754.75 Cr | 13.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹754.75 Cr | 11.9% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.95 Cr | 15.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹200.83 Cr | 19.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹200.83 Cr | 16.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2441.13 Cr | 19.9% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2441.13 Cr | 18.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹809.18 Cr | 13.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.44 Cr | 15.8% |
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (27-Mar-25)
Returns (Since Inception)
Fund Size
₹271 Cr
Expense Ratio
2.39%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+28.94%
+17.95% (Cat Avg.)
Since Inception
+23.82%
— (Cat Avg.)
Equity | ₹251.44 Cr | 92.66% |
Others | ₹19.92 Cr | 7.34% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹29.62 Cr | 10.92% |
Cipla Ltd | Equity | ₹21.9 Cr | 8.07% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.1 Cr | 7.41% |
Divi's Laboratories Ltd | Equity | ₹19.07 Cr | 7.03% |
Lupin Ltd | Equity | ₹14.8 Cr | 5.45% |
Fortis Healthcare Ltd | Equity | ₹10.15 Cr | 3.74% |
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹9.56 Cr | 3.52% |
Torrent Pharmaceuticals Ltd | Equity | ₹9.33 Cr | 3.44% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹8.85 Cr | 3.26% |
Mankind Pharma Ltd | Equity | ₹7.54 Cr | 2.78% |
Apollo Hospitals Enterprise Ltd | Equity | ₹6.84 Cr | 2.52% |
Laurus Labs Ltd | Equity | ₹6.41 Cr | 2.36% |
Ipca Laboratories Ltd | Equity | ₹6.17 Cr | 2.27% |
Abbott India Ltd | Equity | ₹5.91 Cr | 2.18% |
Ajanta Pharma Ltd | Equity | ₹5.89 Cr | 2.17% |
Piramal Pharma Ltd | Equity | ₹5.47 Cr | 2.02% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹5.02 Cr | 1.85% |
Poly Medicure Ltd | Equity | ₹4.77 Cr | 1.76% |
Biocon Ltd | Equity | ₹4.77 Cr | 1.76% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹4.72 Cr | 1.74% |
Global Health Ltd | Equity | ₹4.14 Cr | 1.53% |
Jupiter Life Line Hospitals Ltd | Equity | ₹3.78 Cr | 1.39% |
Vijaya Diagnostic Centre Ltd | Equity | ₹3.56 Cr | 1.31% |
Neuland Laboratories Limited | Equity | ₹3.53 Cr | 1.30% |
Rainbow Childrens Medicare Ltd | Equity | ₹3.32 Cr | 1.22% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹3.24 Cr | 1.19% |
Ami Organics Ltd | Equity | ₹3.11 Cr | 1.14% |
Navin Fluorine International Ltd | Equity | ₹3.09 Cr | 1.14% |
91 Days Tbill Red 08-05-2025 | Bond - Gov't/Treasury | ₹2.96 Cr | 1.09% |
Supriya Lifescience Ltd | Equity | ₹2.87 Cr | 1.06% |
AstraZeneca Pharma India Ltd | Equity | ₹2.64 Cr | 0.97% |
Strides Pharma Science Ltd | Equity | ₹2.63 Cr | 0.97% |
Kovai Medical Center & Hospital Ltd | Equity | ₹2.58 Cr | 0.95% |
RPG Life Sciences Ltd | Equity | ₹2.07 Cr | 0.76% |
Thyrocare Technologies Ltd | Equity | ₹1.98 Cr | 0.73% |
Laxmi Dental Ltd | Equity | ₹1.98 Cr | 0.73% |
364 DTB 23052025 | Bond - Gov't/Treasury | ₹1.97 Cr | 0.73% |
Blue Jet Healthcare Ltd | Equity | ₹1.83 Cr | 0.68% |
Sai Life Sciences Ltd | Equity | ₹1.66 Cr | 0.61% |
Net Receivables / (Payables) | Cash | ₹1.65 Cr | 0.61% |
SRF Ltd | Equity | ₹1.55 Cr | 0.57% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹1.52 Cr | 0.56% |
Shaily Engineering Plastics Ltd | Equity | ₹1.22 Cr | 0.45% |
Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.06 Cr | 0.39% |
91 DTB 20032025 | Bond - Gov't/Treasury | ₹1 Cr | 0.37% |
91 DTB 10042025 | Bond - Gov't/Treasury | ₹0.99 Cr | 0.37% |
91 DTB 17042025 | Bond - Gov't/Treasury | ₹0.99 Cr | 0.37% |
Zota Health Care Ltd | Equity | ₹0.72 Cr | 0.26% |
91 Days Tbill Red 24-04-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.18% |
364 DTB 13032025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.07% |
91 DTB 28032025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.04% |
Large Cap Stocks
29.45%
Mid Cap Stocks
32.59%
Small Cap Stocks
28.58%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹238.93 Cr | 88.05% |
Basic Materials | ₹7.42 Cr | 2.74% |
Industrials | ₹1.55 Cr | 0.57% |
Standard Deviation
This fund
--
Cat. avg.
16.58%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.70
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.18
Higher the better
Since February 2024
Since February 2024
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.39% | Exit Load 1.00% | Fund Size ₹271 Cr | Age 1 year 1 month | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹25.63 Cr | 20.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹754.75 Cr | 13.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹754.75 Cr | 11.9% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.95 Cr | 15.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹200.83 Cr | 19.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹200.83 Cr | 16.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2441.13 Cr | 19.9% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2441.13 Cr | 18.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹809.18 Cr | 13.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.44 Cr | 15.8% |
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments